Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations
Adial Pharmaceuticals (NASDAQ: ADIL) has been granted U.S. patent number 12150931 on November 26, 2024, expanding its intellectual property coverage for treating alcohol and drug dependence. The patent covers broader genotype combinations identified by the company's proprietary genetic diagnostic for targeted treatment of alcohol use disorder (AUD) with AD04, their lead investigational drug. The patent specifically includes HTR3A, HTR3B, and SLC6A4 receptor sites, supporting their precision medicine approach to addiction treatment. This patent protection extends through 2031.
Adial Pharmaceuticals (NASDAQ: ADIL) ha ricevuto il numero di brevetto statunitense 12150931 il 26 novembre 2024, ampliando la sua protezione della proprietà intellettuale per il trattamento della dipendenza da alcol e droghe. Il brevetto copre combinazioni genotipiche più ampie identificate dal diagnostico genetico proprietario dell'azienda per il trattamento mirato del disturbo da uso di alcol (AUD) con AD04, il loro principale farmaco in fase di sperimentazione. Il brevetto include specificamente i siti recettoriali HTR3A, HTR3B e SLC6A4, supportando il loro approccio di medicina di precisione al trattamento delle dipendenze. Questa protezione brevettuale si estende fino al 2031.
Adial Pharmaceuticals (NASDAQ: ADIL) ha recibido el número de patente estadounidense 12150931 el 26 de noviembre de 2024, ampliando su cobertura de propiedad intelectual para el tratamiento de la dependencia del alcohol y las drogas. La patente cubre combinaciones genotípicas más amplias identificadas por el diagnóstico genético propietario de la compañía para el tratamiento dirigido del trastorno por consumo de alcohol (AUD) con AD04, su principal medicamento en investigación. La patente incluye específicamente los sitios de receptores HTR3A, HTR3B y SLC6A4, apoyando su enfoque de medicina de precisión para el tratamiento de la adicción. Esta protección de patente se extiende hasta 2031.
Adial Pharmaceuticals (NASDAQ: ADIL)는 2024년 11월 26일 미국 특허 번호 12150931을 받았으며, 이로써 알코올 및 약물 의존 치료를 위한 지적 재산권 범위를 확장하게 되었습니다. 이 특허는 회사의 독점 유전 진단법으로 확인된 보다 넓은 유전자 조합을 포함하며, 알코올 사용 장애(AUD)를 AD04, 그들의 주요 연구 약물로 표적 치료하기 위해 설계되었습니다. 이 특허는 HTR3A, HTR3B, SLC6A4 수용체 부위를 구체적으로 포함하여 중독 치료에 대한 정밀 의학 접근 방식을 지원합니다. 이 특허 보호는 2031년까지 유효합니다.
Adial Pharmaceuticals (NASDAQ: ADIL) a obtenu le numéro de brevet américain 12150931 le 26 novembre 2024, élargissant ainsi sa couverture de propriété intellectuelle pour le traitement de la dépendance à l'alcool et aux drogues. Le brevet couvre des combinaisons génotypiques plus larges identifiées par le diagnostic génétique propriétaire de l'entreprise pour le traitement ciblé du trouble lié à l'usage de l'alcool (AUD) avec AD04, leur principal médicament en cours d'essai. Le brevet inclut spécifiquement les sites récepteurs HTR3A, HTR3B et SLC6A4, soutenant leur approche de médecine de précision dans le traitement des addictions. Cette protection par brevet s'étend jusqu'en 2031.
Adial Pharmaceuticals (NASDAQ: ADIL) hat am 26. November 2024 die US-Patentnummer 12150931 erhalten, wodurch der Schutz des geistigen Eigentums für die Behandlung von Alkohol- und Drogenabhängigkeit erweitert wird. Das Patent deckt breitere Genotypkombinationen ab, die durch das proprietäre genetische Diagnosetools des Unternehmens für die zielgerichtete Behandlung des Alkoholkonsumsstörung (AUD) mit AD04, ihrem leitenden Prüfmedikament, identifiziert wurden. Das Patent umfasst spezifisch die Rezeptorstellen HTR3A, HTR3B und SLC6A4, was ihren Ansatz der Präzisionsmedizin zur Behandlung von Sucht unterstützt. Dieser Patentschutz gilt bis 2031.
- Secured new U.S. patent expanding IP protection through 2031
- Patent covers broader range of genotype combinations for AUD treatment
- Enhanced protection for proprietary genetic diagnostic technology
- None.
Insights
The newly granted patent significantly strengthens Adial's intellectual property position in personalized addiction treatment. The expanded coverage of genotype combinations for HTR3A, HTR3B and SLC6A4 receptor sites creates substantial barriers to entry for competitors through 2031. The patent's scope specifically targets diagnostic-guided treatment of alcohol use disorder (AUD), positioning Adial uniquely in the precision medicine space. Key strategic value lies in the comprehensive protection of all possible genotype combinations identified in clinical programs, making it challenging for competitors to develop similar genetically-targeted treatments without potential infringement.
While the patent enhances Adial's commercial potential, investors should note the company's small market cap of
GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12150931 was issued on November 26, 2024 by the United States Patent and Trademark Office, expanding the Company’s intellectual property coverage.
The patent covers a broader range of genotype combinations identified by the Company’s proprietary genetic diagnostic for targeted treatment of alcohol use disorder (AUD) with AD04, the Company’s lead investigational new drug product. These genotype combinations include the HTR3A, HTR3B, and SLC6A4 receptor sites which are expected to play an important role in the Company’s precision medicine approach to treating addiction and may support the expansion of its pipeline.
“This patent significantly enhances our intellectual property portfolio, providing us with greater flexibility and protection as we advance AD04 toward commercialization,” said Cary Claiborne, CEO of Adial Pharmaceuticals. “We are broadening our patent estate for AD04 and its use in the field of personalized medicine by securing expanded coverage of these genotype combinations. This granted patent is an important part of our strategy to protect AD04 for the treatment of AUD by patenting all possible combinations of genotypes identified in the clinical program and strengthening our IP protection through 2031. The goal is to obtain the broadest patent estate coverage possible of any genetically targeted addiction related pharmaceutical asset.”
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
If you are interested in exploring partnership opportunities with Adial, we invite you to reach out to us (BD@adialpharma.com) to discuss how our joint efforts can bring about positive change in the millions of patients who are struggling with addiction.
Forward-Looking Statements
This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the HTR3A, HTR3B, and SLC6A4 receptor sites playing an important role in our precision medicine approach to treating addiction and supporting the expansion of our pipeline, advancing AD04 toward commercialization, obtaining the broadest patent estate coverage possible of any genetically targeted addiction related pharmaceutical asset and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: ADIL@crescendo-ir.com
FAQ
What is the new patent number granted to Adial Pharmaceuticals (ADIL)?
Which receptor sites are covered in Adial Pharmaceuticals' (ADIL) new patent?
How long does Adial Pharmaceuticals' (ADIL) new patent protection extend?
What is the main purpose of Adial Pharmaceuticals' (ADIL) new patent?
